No Cover Image

E-Thesis 552 views 115 downloads

Clinically Actionable Biomarker Identification in Solid Tumour Diagnostic Cellular Pathology / ALISON FINALL

Swansea University Author: ALISON FINALL

  • 2025_Finall_A.final.71426.pdf

    PDF | E-Thesis – open access

    Copyright: the author, Alison Finall, 2026. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).

    Download (4.01MB)

DOI (Published version): 10.23889/SUThesis.71426

Abstract

The landscape of tumour testing for genomic alterations is developing at an exceptionally fast pace and applies to all solid tumours now that tumour agnostic testing is required in patients who have failed standard oncology treatments with evidence of clinical and radiological progression (1-5) .The...

Full description

Published: Swansea University
Institution: Swansea University
Degree level: Doctoral
Degree name: M.D
Supervisor: Morgan, C.
URI: https://cronfa.swan.ac.uk/Record/cronfa71426
first_indexed 2026-02-16T15:19:22Z
last_indexed 2026-02-17T05:35:18Z
id cronfa71426
recordtype RisThesis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2026-02-16T16:01:04.6834816</datestamp><bib-version>v2</bib-version><id>71426</id><entry>2026-02-16</entry><title>Clinically Actionable Biomarker Identification in Solid Tumour Diagnostic Cellular Pathology</title><swanseaauthors><author><sid>6deafb7f21945a982ac0673bc547fb40</sid><firstname>ALISON</firstname><surname>FINALL</surname><name>ALISON FINALL</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2026-02-16</date><abstract>The landscape of tumour testing for genomic alterations is developing at an exceptionally fast pace and applies to all solid tumours now that tumour agnostic testing is required in patients who have failed standard oncology treatments with evidence of clinical and radiological progression (1-5) .The focus of the collection of the published works for presentation in this thesis examines how we might do things differently within histopathology laboratories to improve patient experiences, efficiency of workflows and clinical pathways for patients with non-squamous, non-small cell lung carcinoma (NSCLC) and metastatic malignant melanoma.The following papers form the submission for a Medical Doctorate degree. The research and literature reviews investigate, evidence and improve biomarker identification commenced following discovery of rapid, near patient, fully automated technology at the Royal Brompton Hospital, Thoracic Pathology Update Course in London May 2016</abstract><type>E-Thesis</type><journal/><volume/><journalNumber/><paginationStart/><paginationEnd/><publisher/><placeOfPublication>Swansea University</placeOfPublication><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic/><keywords>Biomarkers, solid tumour, somatic gene testing</keywords><publishedDay>0</publishedDay><publishedMonth>0</publishedMonth><publishedYear>0</publishedYear><publishedDate>0001-01-01</publishedDate><doi>10.23889/SUThesis.71426</doi><url/><notes/><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><supervisor>Morgan, C.</supervisor><degreelevel>Doctoral</degreelevel><degreename>M.D</degreename><apcterm/><funders/><projectreference/><lastEdited>2026-02-16T16:01:04.6834816</lastEdited><Created>2026-02-16T13:34:19.5044257</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>ALISON</firstname><surname>FINALL</surname><order>1</order></author></authors><documents><document><filename>71426__36242__e5da48bcf0504f54a255de038d20d7c6.pdf</filename><originalFilename>2025_Finall_A.final.71426.pdf</originalFilename><uploaded>2026-02-16T15:16:27.9502536</uploaded><type>Output</type><contentLength>4204942</contentLength><contentType>application/pdf</contentType><version>E-Thesis &#x2013; open access</version><cronfaStatus>true</cronfaStatus><documentNotes>Copyright: the author, Alison Finall, 2026. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2026-02-16T16:01:04.6834816 v2 71426 2026-02-16 Clinically Actionable Biomarker Identification in Solid Tumour Diagnostic Cellular Pathology 6deafb7f21945a982ac0673bc547fb40 ALISON FINALL ALISON FINALL true false 2026-02-16 The landscape of tumour testing for genomic alterations is developing at an exceptionally fast pace and applies to all solid tumours now that tumour agnostic testing is required in patients who have failed standard oncology treatments with evidence of clinical and radiological progression (1-5) .The focus of the collection of the published works for presentation in this thesis examines how we might do things differently within histopathology laboratories to improve patient experiences, efficiency of workflows and clinical pathways for patients with non-squamous, non-small cell lung carcinoma (NSCLC) and metastatic malignant melanoma.The following papers form the submission for a Medical Doctorate degree. The research and literature reviews investigate, evidence and improve biomarker identification commenced following discovery of rapid, near patient, fully automated technology at the Royal Brompton Hospital, Thoracic Pathology Update Course in London May 2016 E-Thesis Swansea University Biomarkers, solid tumour, somatic gene testing 0 0 0 0001-01-01 10.23889/SUThesis.71426 COLLEGE NANME COLLEGE CODE Swansea University Morgan, C. Doctoral M.D 2026-02-16T16:01:04.6834816 2026-02-16T13:34:19.5044257 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science ALISON FINALL 1 71426__36242__e5da48bcf0504f54a255de038d20d7c6.pdf 2025_Finall_A.final.71426.pdf 2026-02-16T15:16:27.9502536 Output 4204942 application/pdf E-Thesis – open access true Copyright: the author, Alison Finall, 2026. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0). true eng https://creativecommons.org/licenses/by/4.0/
title Clinically Actionable Biomarker Identification in Solid Tumour Diagnostic Cellular Pathology
spellingShingle Clinically Actionable Biomarker Identification in Solid Tumour Diagnostic Cellular Pathology
ALISON FINALL
title_short Clinically Actionable Biomarker Identification in Solid Tumour Diagnostic Cellular Pathology
title_full Clinically Actionable Biomarker Identification in Solid Tumour Diagnostic Cellular Pathology
title_fullStr Clinically Actionable Biomarker Identification in Solid Tumour Diagnostic Cellular Pathology
title_full_unstemmed Clinically Actionable Biomarker Identification in Solid Tumour Diagnostic Cellular Pathology
title_sort Clinically Actionable Biomarker Identification in Solid Tumour Diagnostic Cellular Pathology
author_id_str_mv 6deafb7f21945a982ac0673bc547fb40
author_id_fullname_str_mv 6deafb7f21945a982ac0673bc547fb40_***_ALISON FINALL
author ALISON FINALL
author2 ALISON FINALL
format E-Thesis
institution Swansea University
doi_str_mv 10.23889/SUThesis.71426
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 1
active_str 0
description The landscape of tumour testing for genomic alterations is developing at an exceptionally fast pace and applies to all solid tumours now that tumour agnostic testing is required in patients who have failed standard oncology treatments with evidence of clinical and radiological progression (1-5) .The focus of the collection of the published works for presentation in this thesis examines how we might do things differently within histopathology laboratories to improve patient experiences, efficiency of workflows and clinical pathways for patients with non-squamous, non-small cell lung carcinoma (NSCLC) and metastatic malignant melanoma.The following papers form the submission for a Medical Doctorate degree. The research and literature reviews investigate, evidence and improve biomarker identification commenced following discovery of rapid, near patient, fully automated technology at the Royal Brompton Hospital, Thoracic Pathology Update Course in London May 2016
published_date 0001-01-01T07:00:56Z
_version_ 1861427980430999552
score 11.100739

Similar Items